NervGen Pharma Appoints Keith Vendola as CFO to Advance NVG-291 RESTORE Trial
NervGen Pharma has named Dr. Keith Vendola as Chief Financial Officer, effective immediately, to lead financial strategy and corporate development. He brings over 20 years of biopharma finance expertise, including CFO roles at Wugen and IO Biotech, to support initiation of the RESTORE study for NVG-291 in chronic tetraplegia.
1. Leadership Appointment
NervGen Pharma has appointed Keith Vendola, MD, MBA, as Chief Financial Officer effective immediately. In his new role, he will direct the company’s financial strategy, oversee corporate development initiatives and manage capital markets activity to support NervGen’s growth trajectory.
2. Extensive Biopharma Finance Experience
Vendola brings more than two decades of industry expertise, having served as CFO at Wugen and IO Biotech, led financial transformation and Nasdaq listing efforts at Rezolute, and held strategic roles at Coherus BioSciences as well as healthcare investment banking positions at BofA Securities and JPMorgan Chase.
3. Supporting NVG-291 RESTORE Trial
With Vendola at the financial helm, NervGen is positioned to advance its lead candidate, NVG-291, into the RESTORE registrational study for chronic tetraplegia. His oversight will be critical for funding and strategic planning as the company progresses its neuroreparative therapeutics pipeline.